Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Invasive strategies for rhythm control of atrial fibrillation: a narrative review

  • Hong-Ju Kim (Division of Cardiology, Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Chan-Hee Lee (Division of Cardiology, Department of Internal Medicine, Yeungnam University College of Medicine)
  • 투고 : 2024.07.09
  • 심사 : 2024.08.28
  • 발행 : 2024.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Atrial fibrillation (AF) is the most common sustained tachyarrhythmia and its increasing prevalence has resulted in a growing health-care burden. A recent landmark randomized trial, the EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), highlighted the importance of early rhythm control in AF, which was previously underemphasized. Rhythm control therapy includes antiarrhythmic drugs, direct-current cardioversion, and catheter ablation. Currently, catheter ablation is indicated for patients with AF who are either refractory or intolerant to antiarrhythmic drugs or who exhibit decreased left ventricular systolic function. Catheter ablation can be categorized according to the energy source used, including radiofrequency ablation (RFA), cryoablation, laser ablation, and the recently emerging pulsed field ablation (PFA). Catheter ablation techniques can also be divided into the point-by-point ablation method, which ablates the pulmonary vein (PV) antrum one point at a time, and the single-shot technique, which uses a spherical catheter to ablate the PV antrum in a single application. PFA is known to be applicable to both point-by-point and single-shot techniques and is expected to be promising owing to its tissue specificity, resulting in less collateral damage than catheter ablation involving thermal energy, such as RFA and cryoablation. In this review, we aimed to outline catheter ablation for rhythm control in AF by reviewing previous studies.

키워드

과제정보

We thank the Yeungnam University College of Medicine research support team (design director: Hyun Yoon Choi) for providing the illustrations used in this study.

참고문헌

  1. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013;128:2192-201.  https://doi.org/10.1161/CIRCULATIONAHA.112.000491
  2. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-53.  https://doi.org/10.1093/eurheartj/ehv466
  3. Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart 2018;104:2010-7.  https://doi.org/10.1136/heartjnl-2017-312930
  4. Bunch TJ. Atrial fibrillation and dementia. Circulation 2020;142:618-20.  https://doi.org/10.1161/CIRCULATIONAHA.120.045866
  5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guideline for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.  https://doi.org/10.1093/eurheartj/ehaa612
  6. Giannone ME, Filippini T, Whelton PK, Chiari A, Vitolo M, Boriani G, et al. Atrial fibrillation and the risk of early-onset dementia: a systematic review and meta-analysis. J Am Heart Assoc 2022;11:e025653. 
  7. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77.  https://doi.org/10.1056/NEJMoa0708789
  8. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-86.  https://doi.org/10.1378/chest.126.2.476
  9. Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD, et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). Am J Cardiol 2003;92:468-72.  https://doi.org/10.1016/S0002-9149(03)00671-4
  10. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.  https://doi.org/10.1056/NEJMoa021328
  11. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.  https://doi.org/10.1056/NEJMoa021375
  12. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF). A randomised trial. Lancet 2000;356:1789-94.  https://doi.org/10.1016/S0140-6736(00)03230-X
  13. Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ 2021;373:n991. 
  14. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305-16.  https://doi.org/10.1056/NEJMoa2019422
  15. Kalman JM, Al-Kaisey AM, Parameswaran R, Hawson J, Anderson RD, Lim M, et al. Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur Heart J 2023;44:2447-54.  https://doi.org/10.1093/eurheartj/ehad247
  16. Bunch TJ, May HT, Bair TL, Johnson DL, Weiss JP, Crandall BG, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm 2013;10:1257-62.  https://doi.org/10.1016/j.hrthm.2013.05.013
  17. De Greef Y, Schwagten B, Chierchia GB, de Asmundis C, Stockman D, Buysschaert I. Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and longterm outcome in atrial fibrillation: results from the Middelheim-PVI Registry. Europace 2018;20:589-95.  https://doi.org/10.1093/europace/euw426
  18. Yu HT, Kim IS, Kim TH, Uhm JS, Kim JY, Joung B, et al. Persistent atrial fibrillation over 3 years is associated with higher recurrence after catheter ablation. J Cardiovasc Electrophysiol 2020;31:457-64.  https://doi.org/10.1111/jce.14345
  19. De Greef Y, Bogaerts K, Sofianos D, Buysschaert I. Impact of diagnosis-to-ablation time on AF recurrence: pronounced the first 3 years, irrelevant thereafter. JACC Clin Electrophysiol 2023;9:2263-72. 
  20. Turakhia MP, Guo JD, Keshishian A, Delinger R, Sun X, Ferri M, et al. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. Clin Cardiol 2023;46:484-93.  https://doi.org/10.1002/clc.23983
  21. Tsao CW, Aday AW, Almarzooq ZI, Anderson CA, Arora P, Avery CL, et al. Heart disease and stroke statistics: 2023 update. A report from the American Heart Association. Circulation 2023;147:e93-621.  https://doi.org/10.1161/CIR.0000000000001137
  22. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.  https://doi.org/10.1161/CIRCULATIONAHA.113.005119
  23. Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J 2018;202:20-6.  https://doi.org/10.1016/j.ahj.2018.04.017
  24. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6.  https://doi.org/10.1161/01.CIR.0000140263.20897.42
  25. Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, et al. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace 2017;19:190-225. 
  26. Miller JD, Aronis KN, Chrispin J, Patil KD, Marine JE, Martin SS, et al. Obesity, exercise, obstructive sleep apnea, and modifiable atherosclerotic cardiovascular disease risk factors in atrial fibrillation. J Am Coll Cardiol 2015;66:2899-906.  https://doi.org/10.1016/j.jacc.2015.10.047
  27. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-76.  https://doi.org/10.1016/j.jacc.2014.03.022
  28. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.  https://doi.org/10.1093/eurheartj/ehq278
  29. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.  https://doi.org/10.1001/jama.1994.03510350050036
  30. Cox JL, Schuessler RB, D'Agostino HJ, Stone CM, Chang BC, Cain ME, et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991;101:569-83.  https://doi.org/10.1016/S0022-5223(19)36684-X
  31. Prasad SM, Maniar HS, Camillo CJ, Schuessler RB, Boineau JP, Sundt TM, et al. The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg 2003;126:1822-8.  https://doi.org/10.1016/S0022-5223(03)01287-X
  32. Gaynor SL, Schuessler RB, Bailey MS, Ishii Y, Boineau JP, Gleva MJ, et al. Surgical treatment of atrial fibrillation: predictors of late recurrence. J Thorac Cardiovasc Surg 2005;129:104-11.  https://doi.org/10.1016/j.jtcvs.2004.08.042
  33. Johansson BI, Vaart O, Edvardsson N, Nystrom B, Schersten H, Karlsson T, et al. Low mortality and low rate of perceived and documented arrhythmias after Cox maze III surgery for atrial fibrillation. Pacing Clin Electrophysiol 2014;37:147-56.  https://doi.org/10.1111/pace.12286
  34. Haissaguerre M, Shah DC, Jais P, Hocini M, Yamane T, Deisenhofer I, et al. Electrophysiological breakthroughs from the left atrium to the pulmonary veins. Circulation 2000;102:2463-5.  https://doi.org/10.1161/01.CIR.102.20.2463
  35. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-66.  https://doi.org/10.1056/NEJM199809033391003
  36. Pappone C, Oreto G, Rosanio S, Vicedomini G, Tocchi M, Gugliotta F, et al. Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation. Circulation 2001;104:2539-44.  https://doi.org/10.1161/hc4601.098517
  37. Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation. Circulation 2000;102:2619-28.  https://doi.org/10.1161/01.CIR.102.21.2619
  38. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015;372:1812-22.  https://doi.org/10.1056/NEJMoa1408288
  39. He X, Zhou Y, Chen Y, Wu L, Huang Y, He J. Left atrial posterior wall isolation reduces the recurrence of atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol 2016;46:267-74.  https://doi.org/10.1007/s10840-016-0124-7
  40. Scott PA, Silberbauer J, Murgatroyd FD. The impact of adjunctive complex fractionated atrial electrogram ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta-analysis. Europace 2016;18:359-67.  https://doi.org/10.1093/europace/euv351
  41. Lee JM, Shim J, Park J, Yu HT, Kim TH, Park JK, et al. The electrical isolation of the left atrial posterior wall in catheter ablation of persistent atrial fibrillation. JACC Clin Electrophysiol 2019;5:1253-61.  https://doi.org/10.1016/j.jacep.2019.08.021
  42. Kistler PM, Chieng D, Sugumar H, Ling LH, Segan L, Azzopardi S, et al. Effect of catheter ablation using pulmonary vein isolation with vs without posterior left atrial wall isolation on atrial arrhythmia recurrence in patients with persistent atrial fibrillation: the CAPLA randomized clinical trial. JAMA 2023;329:127-35.  https://doi.org/10.1001/jama.2022.23722
  43. Writing Committee Members; Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024;83:109-279. 
  44. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:e275-444.  https://doi.org/10.1016/j.hrthm.2017.05.012
  45. Morady F, Scheinman MM. Transvenous catheter ablation of a posteroseptal accessory pathway in a patient with the Wolff-Parkinson-White syndrome. N Engl J Med 1984;310:705-7.  https://doi.org/10.1056/NEJM198403153101108
  46. Houmsse M, Daoud EG. Biophysics and clinical utility of irrigated-tip radiofrequency catheter ablation. Expert Rev Med Devices 2012;9:59-70.  https://doi.org/10.1586/erd.11.42
  47. Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol 2014;64:647-56.  https://doi.org/10.1016/j.jacc.2014.04.072
  48. Reddy VY, Pollak S, Lindsay BD, McElderry HT, Natale A, Kantipudi C, et al. Relationship between catheter stability and 12-month success after pulmonary vein isolation: a subanalysis of the SMART-AF trial. JACC Clin Electrophysiol 2016;2:691-9.  https://doi.org/10.1016/j.jacep.2016.07.014
  49. Macle L, Frame D, Gache LM, Monir G, Pollak SJ, Boo LM. Atrial fibrillation ablation with a spring sensor-irrigated contact force-sensing catheter compared with other ablation catheters: systematic literature review and meta-analysis. BMJ Open 2019;9:e023775. 
  50. Duytschaever M, Vijgen J, De Potter T, Scherr D, Van Herendael H, Knecht S, et al. Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trial. Europace 2020;22:1645-52. https://doi.org/10.1093/europace/euaa157
  51. Natale A, Monir G, Patel AM, Fishel RS, Marchlinski FE, Delaughter MC, et al. Long-term safety and effectiveness of paroxysmal atrial fibrillation ablation using a porous tip contact force-sensing catheter from the SMART SF trial. J Interv Card Electrophysiol 2021;61:63-9.  https://doi.org/10.1007/s10840-020-00780-4
  52. Habibi M, Berger RD, Calkins H. Radiofrequency ablation: technological trends, challenges, and opportunities. Europace 2021;23:511-9.  https://doi.org/10.1093/europace/euaa328
  53. Suga K, Kato H, Akita S, Sakurai T, Ota R, Okada T, et al. Optimal ablation settings of TactiFlex SE laser-cut irrigated-tip catheter: comparison with ThermoCool SmartTouch SurroundFlow porous irrigated-tip catheter. J Interv Card Electrophysiol 2024 Apr 4 [Epub]. https://doi.org/10.1007/s10840-024-01797-9. 
  54. Naniwadekar A, Dukkipati SR. High-power short-duration ablation of atrial fibrillation: a contemporary review. Pacing Clin Electrophysiol 2021;44:528-40.  https://doi.org/10.1111/pace.14167
  55. Leshem E, Zilberman I, Tschabrunn CM, Barkagan M, Contreras-Valdes FM, Govari A, et al. High-power and short-duration ablation for pulmonary vein isolation: biophysical characterization. JACC Clin Electrophysiol 2018;4:467-79.  https://doi.org/10.1016/j.jacep.2017.11.018
  56. Baher A, Kheirkhahan M, Rechenmacher SJ, Marashly Q, Kholmovski EG, Siebermair J, et al. High-power radiofrequency catheter ablation of atrial fibrillation: using late gadolinium enhancement magnetic resonance imaging as a novel index of esophageal injury. JACC Clin Electrophysiol 2018;4:1583-94.  https://doi.org/10.1016/j.jacep.2018.07.017
  57. Ravi V, Poudyal A, Abid QU, Larsen T, Krishnan K, Sharma PS, et al. High-power short duration vs. conventional radiofrequency ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2021;23:710-21.  https://doi.org/10.1093/europace/euaa327
  58. Osorio J, Hussein AA, Delaughter MC, Monir G, Natale A, Dukkipati S, et al. Very high-power short-duration, temperature-controlled radiofrequency ablation in paroxysmal atrial fibrillation: the prospective multicenter Q-FFICIENCY trial. JACC Clin Electrophysiol 2023;9:468-80.  https://doi.org/10.1016/j.jacep.2022.10.019
  59. Hussein AA, Delaughter MC, Monir G, Natale A, Dukkipati S, Oza S, et al. Paroxysmal atrial fibrillation ablation with a novel temperature-controlled CF-sensing catheter: Q-FFICIENCY clinical and healthcare utilization benefits. J Cardiovasc Electrophysiol 2023;34:2493-503.  https://doi.org/10.1111/jce.16093
  60. Andrade JG, Khairy P, Dubuc M. Catheter cryoablation: biology and clinical uses. Circ Arrhythm Electrophysiol 2013;6:218-27.  https://doi.org/10.1161/CIRCEP.112.973651
  61. Avitall B, Kalinski A. Cryotherapy of cardiac arrhythmia: from basic science to the bedside. Heart Rhythm 2015;12:2195-203.  https://doi.org/10.1016/j.hrthm.2015.05.034
  62. Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:2235-45.  https://doi.org/10.1056/NEJMoa1602014
  63. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316-24.  https://doi.org/10.1056/NEJMoa2029554
  64. Straube F, Pongratz J, Kosmalla A, Brueck B, Riess L, Hartl S, et al. Cryoballoon ablation strategy in persistent atrial fibrillation. Front Cardiovasc Med 2021;8:758408. 
  65. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305-15.  https://doi.org/10.1056/NEJMoa2029980
  66. Su WW, Reddy VY, Bhasin K, Champagne J, Sangrigoli RM, Braegelmann KM, et al. Cryoballoon ablation of pulmonary veins for persistent atrial fibrillation: results from the multicenter STOP Persistent AF trial. Heart Rhythm 2020;17:1841-7.  https://doi.org/10.1016/j.hrthm.2020.06.020
  67. Metzner A, Rausch P, Lemes C, Reissmann B, Bardyszewski A, Tilz R, et al. The incidence of phrenic nerve injury during pulmonary vein isolation using the second-generation 28 mm cryoballoon. J Cardiovasc Electrophysiol 2014;25:466-70.  https://doi.org/10.1111/jce.12358
  68. Furnkranz A, Bordignon S, Schmidt B, Perrotta L, Dugo D, De Lazzari M, et al. Incidence and characteristics of phrenic nerve palsy following pulmonary vein isolation with the second-generation as compared with the first-generation cryoballoon in 360 consecutive patients. Europace 2015;17:574-8.  https://doi.org/10.1093/europace/euu320
  69. Abugattas JP, de Asmundis C, Iacopino S, Salghetti F, Takarada K, Coutino HE, et al. Phrenic nerve injury during right inferior pulmonary vein ablation with the second-generation cryoballoon: clinical, procedural, and anatomical characteristics. Europace 2018;20:e156-63.  https://doi.org/10.1093/europace/eux337
  70. Hoffmann E, Straube F, Wegscheider K, Kuniss M, Andresen D, Wu LQ, et al. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation. Europace 2019;21:1313-24.  https://doi.org/10.1093/europace/euz155
  71. Dukkipati SR, Cuoco F, Kutinsky I, Aryana A, Bahnson TD, Lakkireddy D, et al. Pulmonary vein isolation using the visually guided laser balloon: a prospective, multicenter, and randomized comparison to standard radiofrequency ablation. J Am Coll Cardiol 2015;66:1350-60.  https://doi.org/10.1016/j.jacc.2015.07.036
  72. Bordignon S, Chun KR, Gunawardene M, Urban V, Kulikoglu M, Miehm K, et al. Energy titration strategies with the endoscopic ablation system: lessons from the high-dose vs. low-dose laser ablation study. Europace 2013;15:685-9.  https://doi.org/10.1093/europace/eus352
  73. Reynolds MR, Zheng Q, Doros G. Laser balloon ablation for AF: a systematic review and meta-analysis. J Cardiovasc Electrophysiol 2018;29:1363-70.  https://doi.org/10.1111/jce.13698
  74. Weber S, Hoher M, Schultes D. First results and follow-up of a second-generation circular mapping and ablation catheter. J Interv Card Electrophysiol 2016;47:213-9.  https://doi.org/10.1007/s10840-016-0140-7
  75. Monnig G, Eckardt L. Multielectrode Pulmonary Vein Ablation Catheter (PVAC(®)): current data on results and risks. Herzschrittmacherther Elektrophysiol 2014;25:236-40.  https://doi.org/10.1007/s00399-014-0330-x
  76. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 2011;22:961-8.  https://doi.org/10.1111/j.1540-8167.2011.02050.x
  77. Bulava A, Hanis J, Sitek D, Osmera O, Karpianus D, Snorek M, et al. Catheter ablation for paroxysmal atrial fibrillation: a randomized comparison between multielectrode catheter and point-by-point ablation. Pacing Clin Electrophysiol 2010;33:1039-46.  https://doi.org/10.1111/j.1540-8159.2010.02807.x
  78. Vurma M, Dang L, Brunner-La Rocca HP, Sutsch G, Attenhofer-Jost CH, Duru F, et al. Safety and efficacy of the nMARQ catheter for paroxysmal and persistent atrial fibrillation. Europace 2016;18:1164-9.  https://doi.org/10.1093/europace/euw048
  79. Mahida S, Hooks DA, Nentwich K, Ng GA, Grimaldi M, Shin DI, et al. nMARQ ablation for atrial fibrillation: results from a multicenter study. J Cardiovasc Electrophysiol 2015;26:724-9.  https://doi.org/10.1111/jce.12698
  80. Shin DI, Kirmanoglou K, Eickholt C, Schmidt J, Clasen L, Butzbach B, et al. Initial results of using a novel irrigated multielectrode mapping and ablation catheter for pulmonary vein isolation. Heart Rhythm 2014;11:375-83.  https://doi.org/10.1016/j.hrthm.2013.12.008
  81. Reddy VY, Al-Ahmad A, Aidietis A, Daly M, Melton I, Hu Y, et al. A novel visually guided radiofrequency balloon ablation catheter for pulmonary vein isolation: one-year outcomes of the multicenter AF-FICIENT I trial. Circ Arrhythm Electrophysiol 2021;14:e009308. 
  82. Dhillon GS, Honarbakhsh S, Di Monaco A, Coling AE, Lenka K, Pizzamiglio F, et al. Use of a multi-electrode radiofrequency balloon catheter to achieve pulmonary vein isolation in patients with paroxysmal atrial fibrillation: 12-month outcomes of the RADIANCE study. J Cardiovasc Electrophysiol 2020;31:1259-69.  https://doi.org/10.1111/jce.14476
  83. Boersma L. New energy sources and technologies for atrial fibrillation catheter ablation. Europace 2022;24(Suppl 2):ii44-51.  https://doi.org/10.1093/europace/euab258
  84. Maor E, Sugrue A, Witt C, Vaidya VR, DeSimone CV, Asirvatham SJ, et al. Pulsed electric fields for cardiac ablation and beyond: a state-of-the-art review. Heart Rhythm 2019;16:1112-20.  https://doi.org/10.1016/j.hrthm.2019.01.012
  85. Neven K, van Es R, van Driel V, van Wessel H, Fidder H, Vink A, et al. Acute and long-term effects of full-power electroporation ablation directly on the porcine esophagus. Circ Arrhythm Electrophysiol 2017;10:e004672. 
  86. van Driel VJ, Neven K, van Wessel H, Vink A, Doevendans PA, Wittkampf FH. Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm 2015;12:1838-44.  https://doi.org/10.1016/j.hrthm.2015.05.012
  87. du Pre BC, van Driel VJ, van Wessel H, Loh P, Doevendans PA, Goldschmeding R, et al. Minimal coronary artery damage by myocardial electroporation ablation. Europace 2013;15:144-9.  https://doi.org/10.1093/europace/eus171
  88. Ekanem E, Reddy VY, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF). Europace 2022;24:1256-66.  https://doi.org/10.1093/europace/euac050
  89. Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol 2019;74:315-26.  https://doi.org/10.1016/j.jacc.2019.04.021
  90. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med 2023;389:1660-71.  https://doi.org/10.1056/NEJMoa2307291
  91. Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, et al. Paroxysmal atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter integrated with a 3-dimensional mapping system: 1-year outcomes of the multicenter inspIRE study. Circ Arrhythm Electrophysiol 2023;16:e011780. 
  92. Di Biase L, Marazzato J, Govari A, Altman A, Beeckler C, Keyes J, et al. Pulsed field ablation index-guided ablation for lesion formation: impact of contact force and number of applications in the ventricular model. Circ Arrhythm Electrophysiol 2024;17: e012717. 
  93. Di Biase L, Marazzato J, Zou F, Lin A, Grupposo V, Chowdhuri N, et al. Point-by-point pulsed field ablation using a multimodality generator and a contact force-sensing ablation catheter: comparison with radiofrequency ablation in a remapped chronic swine heart. Circ Arrhythm Electrophysiol 2023;16:663-71. https://doi.org/10.1161/CIRCEP.123.012344